{
    "nct_id": "NCT04246671",
    "official_title": "Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.",
    "inclusion_criteria": "General inclusion criteria, apply to all cohorts:\n\n* Men and women ≥18 years old.\n* Patients must have histologically documented malignant tumor which is unresectable locally advanced or metastatic.\n* ECOG performance status 0 or 1\n* Patients must have normal organ and bone marrow function as defined in the protocol.\n* Normal left ventricular ejection fraction (LVEF) ≥50%.\n* Troponin I within normal limits.\n* A maximum cumulative dose of prior doxorubicin ≤360 mg/m2 or epirubicin ≤720 mg/m2\n* Any approved cancer therapy (except HER2 antibodies) must be completed at least 3 weeks or 5 half-lives for small molecule inhibitors, whichever is shorter, prior to the first planned dose of TVH vaccine.\n* HER-2 positive cancer: Patients are required to be on active treatment with HER2 antibodies (trastuzumab) prior to and during study treatment.\n* Chordoma patients with progressive extracranial chordoma (base of skull is permitted) not amenable for surgical resection with curative intent, nor for radiation therapy will be enrolled.\n* Patients must have recovered (Grade 1 or baseline) from any clinically significant toxicity associated with prior therapy.\n* Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known metastatic disease to the central nervous system, unless previously treated and responded with a minimum stable disease over 2 CT scans separated at least 4 weeks from each other, and more than 6 weeks since the last dose of dexamethasone.\n* History of allergy or untoward reaction to prior vaccination with vaccinia virus, aminoglycoside antibiotics, ciprofloxacin, or egg products.\n* Subjects should have no known evidence of being immunocompromised.\n* Chronic administration (defined as >5 consecutive days of >15 mg of prednisone (or equivalent) per day) of systemic corticosteroids within 14 days of the first planned dose of TAEK-VAC-HerBy vaccine. Use of inhaled steroids, nasal sprays, eye drops, and topical creams is allowed. Steroids premedication for CT scans is allowed.\n* Clinically significant cardiomyopathy, coronary disease, congestive heart failure (NYHA class III or IV) or reduced as per institutional standards LVEF, poorly controlled hypertension (systolic >180 mm Hg or diastolic >100 mm Hg) or cerebrovascular accident within 1 year.\n* Known history of, or any evidence of active, non-infectious pneumonitis or primary pulmonary fibrosis.",
    "miscellaneous_criteria": ""
}